New heart drug aims to ease debilitating symptoms in genetic heart condition

NCT ID NCT07023614

Recruiting now Disease control Sponsor: Imbria Pharmaceuticals, Inc. Source: ClinicalTrials.gov ↗

Summary

This study is testing whether an investigational drug called ninerafaxstat can improve symptoms and exercise ability in people with a genetic heart condition where the heart muscle is abnormally thick. About 165 participants with symptomatic non-obstructive HCM will receive either the drug or a placebo, in addition to their standard care. The main goal is to see if the drug improves patients' quality of life and how efficiently their body uses oxygen during exercise.

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes NO responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for NON-OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Show contact details

Study contacts

Contact

Phone: •••-•••-•••• Email: •••••@•••••

Locations

Imbria Investigational Site
RECRUITING

La Jolla, California, 92037, United States

Contact Phone: •••-•••-••••
Imbria Investigational Site
RECRUITING

San Francisco, California, 94143, United States

Contact Phone: •••-•••-••••
Imbria Investigational Site
RECRUITING

Washington D.C., District of Columbia, 20010, United States

Contact Phone: •••-•••-••••
Imbria Investigational Site
RECRUITING

Chicago, Illinois, 60611, United States

Contact Phone: •••-•••-••••

Contact Phone: •••-•••-••••
Imbria Investigational Site
RECRUITING

Boston, Massachusetts, 02114, United States

Contact Phone: •••-•••-••••
Imbria Investigational Site
RECRUITING

Burlington, Massachusetts, 01805, United States

Contact Phone: •••-•••-••••
Imbria Investigational Site
RECRUITING

St Louis, Missouri, 63110, United States

Contact Phone: •••-•••-••••
Imbria Investigational Site
RECRUITING

Houston, Texas, 77030, United States
Imbria Investigational Site
RECRUITING

Charlottesville, Virginia, 22903, United States

Contact Phone: •••-•••-••••
Imbria Investigational Site
RECRUITING

Montpellier, 34090, France

Contact Phone: •••-•••-••••
Imbria Investigational Site
RECRUITING

Paris, 75015, France

Contact Phone: •••-•••-••••
Imbria Investigational Site
RECRUITING

Saint-Herblain, 44800, France

Contact Phone: •••-•••-••••
Imbria Investigational Site
RECRUITING

Katowice, 40-555, Poland

Contact Phone: •••-•••-••••
Imbria Investigational Site
RECRUITING

Guimarães, 4835-044, Portugal

Contact
Imbria Investigational Site
RECRUITING

Lisbon, 1169-024, Portugal

Contact
Imbria Investigational Site
RECRUITING

Barcelona, Barcelona, 08035, Spain

Contact Phone: •••-•••-••••
Imbria Investigational Site
RECRUITING

A Coruña, Galicia, 15006, Spain

Contact Phone: •••-•••-••••
Imbria Investigational Site
RECRUITING

Madrid, Madrid, 28034, Spain

Contact Phone: •••-•••-••••
Imbria Investigational Site
RECRUITING

Vigo, Pontevedra, 36312, Spain

Contact
Imbria Investigational Site
RECRUITING

Seville, Sevilla, 41013, Spain

Contact Phone: •••-•••-••••
Imbria Investigational Site
RECRUITING

Seville, Sevilla, Spain

Contact Phone: •••-•••-••••
Imbria Investigational Site
RECRUITING

London, England, W12 0HS, United Kingdom

Contact Phone: •••-•••-••••
Imbria Investigational Site
RECRUITING

Glasgow, Scotland, G51 4TF, United Kingdom

Contact Phone: •••-•••-••••

Conditions

Explore the condition pages connected to this study.

NON-OBSTRUCTIVE HYPERTROPHIC CARDIOMYOPATHY